Heart drug study using CT scans to check fat around heart arteries
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a heart medication (SGLT2 inhibitor) affects fat around the heart's arteries in people who have had a heart attack but do not have diabetes or heart failure. It uses a CT scan to measure changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had a recent heart attack or unstable angina
- You had a procedure to open blocked heart arteries (PCI)
- You have at least one heart artery that was not treated during the procedure
- You do not have diabetes
- You do not have heart failure
- You have not taken an SGLT2 inhibitor in the 4 weeks before the study
- You do not have severe liver or kidney disease
- You have no history of repeated urinary or genital infections
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether an SGLT2 inhibitor (a type of diabetes drug) can help prevent heart attacks, strokes, and other heart problems in people with high blood pressure. You may be eligible if you are 60 or older, have high blood pressure, and have had a heart or blood vessel event (like a heart attack or stroke) or have certain risk factors (like smoking, high cholesterol, or obesity).
Hear when a new SGLT2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.